Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Test Your Knowledge Answers Previous | All Articles This Week | Next
This article originally posted 04 November, 2011 and appeared in  Issue 598

Test Your Knowledge Answer #598

Correct Answer =A

Advertisement

This patient has painful peripheral neuropathy that is affecting his quality of life. Two drugs have recently been approved for diabetic neuropathic pain -- duloxetine (a selective norepinephrine reuptake inhibitor) and pregabalin (an antiepileptic agent). In a recent statement on diabetic neuropathy, the American Diabetes Association has recommended a stepwise approach to management that includes the stabilization of glucose control (because hyperglycemia reduces pain thresholds) followed by the addition of antidepressants and then antiepileptic agents; if these treatments fail to control the pain, the use of opioid drugs and a referral to a pain clinic are recommended.

Key Points

  • Painful neuropathy in patients with diabetes is treated with a stepwise approach that includes use of antidepressants and anticonvulsants.

This patient has suboptimal glycemic control; hence, the most appropriate treatment would be to stabilize or improve glucose control and attempt to control the pain with a selective norepinephrine reuptake inhibitor, such as duloxetine, or an anti-epileptic drug. Using an opioid or opioid-like drug, such as oxycodone or tramadol, as the initial treatment for the pain is not appropriate. There is no evidence that topical capsaicin treatment is effective for the management of severe painful neuropathy.

Bibliography
  1. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956-62. [PMID: 15793206] [PubMed

Copyright © 2012 Diabetes In Control, Inc.

Test Your Knowledge Question #597

A 36-year-old woman with type 2 diabetes is seen for a routine follow-up

 

Test Your Knowledge Question #599

Which of the following abnormalities relating to the incretin pathway...

Check out all of our questions on our Test Your Knowledge pages. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 04 November, 2011 and appeared in  Issue 598

Past five issues: Issue 747 | Diabetes Clinical Mastery Series Issue 206 | SGLT-2 Inhibitors Special Edition September 2014 | Issue 746 | Diabetes Clinical Mastery Series Issue 205 |


Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
The Nutrition and Wound Healing Connection
Cynthia Fleck, RN, MBA, BSN

Category: Nutrition
Credits: 1.0
Search Articles On Diabetes In Control